Literature DB >> 28799291

Inaccuracy of patient-reported descriptions of and satisfaction with bowel actions in irritable bowel syndrome.

E P Halmos1,2,3, J R Biesiekierski1,4, E D Newnham1, R E Burgell2, J G Muir1,2, P R Gibson1,2.   

Abstract

BACKGROUND: Perception of diarrhea and constipation differs greatly. This study aimed to correlate subjective and objective assessment of fecal characteristics in irritable bowel syndrome (IBS) patients.
METHODS: Data from two interventional dietary trials with varying FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols) or gluten content were interrogated. Subjects rated their dissatisfaction with stool consistency daily using a visual analog scale during the interventions. Subjects collected stools at the end of each intervention. Each stool was scored according to the King's Stool Chart (KSC). Fecal water content (FWC) was measured on pooled feces by freeze drying, with diarrhea defined as ≥78%. KEY
RESULTS: Seventy IBS (Rome III) and eight healthy subjects were studied. Each subject's self-rating of stool consistency during the most symptomatic diet was approximately double that of their least. Degree of dissatisfaction with stool consistency correlated poorly with changes in FWC and KSC. IBS subtype related poorly to objective measures of stool consistency. Sixty percent of IBS-D subjects had diarrhea on objective measures. Eighty-five percent with IBS-C had hard and formed stools but three patients met the criteria for diarrhea. One healthy subject had diarrhea on FWC and KSC, and six had hard, formed stools. No differences in FWC was observed when subjects consumed differing amounts of FODMAPs or gluten (all P > .200). CONCLUSIONS AND INFERENCES: There are major disparities between patients' stool descriptions and objective features of constipation and diarrhea. Patient-reported bowel habits require more interrogation for accurate IBS subtyping. Varying FODMAP or gluten content of the diet is not associated with consistent change in FWC.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  constipation; diarrhea; fecal water content; stool chart

Mesh:

Year:  2017        PMID: 28799291     DOI: 10.1111/nmo.13187

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  5 in total

1.  Acute Severe Ulcerative Colitis: The Oxford Criteria No Longer Predict In-Hospital Colectomy Rates.

Authors:  Alice C Moore; Brian Bressler
Journal:  Dig Dis Sci       Date:  2019-05-15       Impact factor: 3.199

2.  Low FODMAP Diet for Functional Gastrointestinal Symptoms in Quiescent Inflammatory Bowel Disease: A Systematic Review of Randomized Controlled Trials.

Authors:  Maria G Grammatikopoulou; Dimitrios G Goulis; Konstantinos Gkiouras; Meletios P Nigdelis; Stefanos T Papageorgiou; Theodora Papamitsou; Alastair Forbes; Dimitrios P Bogdanos
Journal:  Nutrients       Date:  2020-11-27       Impact factor: 5.717

3.  Fermentable oligo-, di-, monosaccharides, and polyols (FODMAPs), but not gluten, elicit modest symptoms of irritable bowel syndrome: a double-blind, placebo-controlled, randomized three-way crossover trial.

Authors:  Elise Nordin; Carl Brunius; Rikard Landberg; Per M Hellström
Journal:  Am J Clin Nutr       Date:  2022-02-09       Impact factor: 7.045

4.  A hands-free stool sampling system for monitoring intestinal health and disease.

Authors:  Sonia Grego; Claire M Welling; Graham H Miller; Peter F Coggan; Katelyn L Sellgren; Brian T Hawkins; Geoffrey S Ginsburg; Jose R Ruiz; Deborah A Fisher; Brian R Stoner
Journal:  Sci Rep       Date:  2022-06-27       Impact factor: 4.996

5.  Serum Levels of Fibroblast Growth Factor 19 Correlate with the Severity of Diarrhea and Independently from Intestinal Inflammation in Patients with Inflammatory Bowel Disease or Microscopic Colitis.

Authors:  Ivan Lyutakov; Radislav Nakov; Hristo Valkov; Rositsa Vatcheva-Dobrevska; Borislav Vladimirov; Plamen Penchev
Journal:  Turk J Gastroenterol       Date:  2021-04       Impact factor: 1.852

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.